期刊文献+

A temporary self-expanding metallic stent for malignant colorectal obstruction 被引量:5

A temporary self-expanding metallic stent for malignant colorectal obstruction
下载PDF
导出
摘要 AIM:To investigate the clinical safety and efficacy of a temporary self-expanding metallic stent(SEMS) for malignant colorectal obstruction.METHODS:From September 2007 to June 2012,33 patients with malignant colorectal obstruction were treated with a temporary SEMS.The stent had a tubular configuration with a retrieval lasso attached inside the proximal end of the stent to facilitate its removal.The SEMS was removed one week after placement.Clinical examination,abdominal X-ray and a contrast study were prospectively performed and both initial and follow-up data before and at 1 d,1 wk,and 1 mo,3 mo,6 mo and 12 mo after stent placement were obtained.Data collected on the technical and clinical success of the procedures,complications,need for reinsertion and survival were analyzed.RESULTS:Stent placement and removal were technically successful in all patients with no procedurerelated complications.Post-procedural complications included stent migration(n = 2) and anal pain(n = 2).Clinical success was achieved in 31(93.9%) of 33 patients with resolution of bowel obstruction within 3 d of stent removal.Eleven of the 33 patients died 73.81 ± 23.66 d(range 42-121 d) after removal of the stent without colonic re-obstruction.Clinical success was achieved in another 8 patients without symptoms of obstruction during the follow-up period.Reinsertion of the stent was performed in the remaining 12 patients with re-obstruction after 84.33 ± 51.80 d of follow-up.The mean and median periods of relief of obstructive symptoms were 97.25 ± 9.56 d and 105 ± 17.43 d,respectively,using Kaplan-Meier analysis.CONCLUSION:Temporary SEMS is a safe and effective approach in patients with malignant colorectal obstruction due to low complication rates and good medium-term outcomes. AIM: To investigate the clinical safety and efficacy of a temporary self-expanding metallic stent (SEMS) for malignant colorectal obstruction. METHODS: From September 2007 to June 2012, 33 patients with malignant colorectal obstruction were treated with a temporary SEMS. The stent had a tubular configuration with a retrieval lasso attached inside the proximal end of the stent to facilitate its removal. The SEMS was removed one week after placement. Clinical examination, abdominal X-ray and a contrast study were prospectively performed and both initial and follow-up data before and at 1 d, 1 wk, and 1 mo, 3 mo, 6 mo and 12 mo after stent placement were obtained. Data collected on the technical and clinical success of the procedures, complications, need for reinsertion and survival were analyzed. RESULTS: Stent placement and removal were technically successful in all patients with no procedure-related complications. Post-procedural complications included stent migration (n = 2) and anal pain (n = 2). Clinical success was achieved in 31 (93.9%) of 33 patients with resolution of bowel obstruction within 3 d of stent removal. Eleven of the 33 patients died 73.81 ± 23.66 d (range 42-121 d) after removal of the stent without colonic re-obstruction. Clinical success was achieved in another 8 patients without symptoms of obstruction during the follow-up period. Reinsertion of the stent was performed in the remaining 12 patients with re-obstruction after 84.33 ± 51.80 d of follow-up. The mean and median periods of relief of obstructive symptoms were 97.25 ± 9.56 d and 105 ± 17.43 d, respectively, using Kaplan-Meier analysis. CONCLUSION: Temporary SEMS is a safe and effective approach in patients with malignant colorectal obstruction due to low complication rates and good medium-term outcomes.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第7期1119-1123,共5页 世界胃肠病学杂志(英文版)
关键词 Self-expanding metallic STENTS COLORECTUM MALIGNANT OBSTRUCTION Complications Self-expanding metallic stents Colorectum Malignant obstruction Complications
  • 相关文献

参考文献25

  • 1Sean M Ronnekleiv-Kelly,Gregory D Kennedy.Management of stage Ⅳ rectal cancer: Palliative options[J].World Journal of Gastroenterology,2011,17(7):835-847. 被引量:5
  • 2A. Fischer,H. J. Schrag,M. Goos,R. Obermaier,U. T. Hopt,P. K. Baier.Transanal endoscopic tube decompression of acute colonic obstruction: experience with 51 cases[J]. Surgical Endoscopy . 2008 (3)
  • 3Camunez F,Echenagusia A,Simo G,et al.Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology . 2000
  • 4Khot UP,Lang AW,Murali K,et al.Systematic review of the efficacy and safety of colorectal stents. British Journal of Surgery . 2002
  • 5Baron,TH.Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. New England Journal of Medicine, The . 2001
  • 6Jung GS,Song HY,Kang SG,et al.Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. Radiology . 2000
  • 7Song HY,Kim JH,Shin JH,Kim HC,Yu CS,Kim JC,Kang SG,Yoon CJ,Lee JY,Koo JH,Lee KH,Kim JK,Kim DH,Shin TB,Jung GS,Han YM.A dual-design expandable colorectal stent for malignant colorectal obstruction: results of a multicenter study. Endoscopy . 2007
  • 8Z. Soonawalla,K. Thakur,P. Boorman.Use of self expanding metallic stents in the management of obstruction of the sigmoid colon. American Journal of Roentgenology . 1998
  • 9Akle CA.Endoprostheses for colonic strictures. British Journal of Surgery . 1998
  • 10SEBASTIAN S,JOHNSTON S,GEOGHEGAN T,et al.Pooled analysis of the efficacy and safety of self-expanding metal stent-ing in malignant colorectal obstruction. The American journal of Gastroenterology . 2004

二级参考文献134

  • 1Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol2010; 28:4706-4713.
  • 2Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
  • 3Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
  • 4Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol 2005; 23: 1011-1027.
  • 5Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
  • 6Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Onco12007; 25:1539-1544.
  • 7Saltz-LB, Clarke S- Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Onco12008; 26:2013-2019.
  • 8Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for meta- static colorectal cancer. J Clin Oncol2008; 26:2006-2012.
  • 9Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009; 27:672-680.
  • 10Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225 -249.

共引文献4

同被引文献17

引证文献5

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部